Pembrolizumab was the first immune checkpoint inhibitor (ICI) of programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) approved in the United States (US) as a first-line treatment for metastatic non-small cell lung cancer (NSCLC). This evidence concerns the gene CD274 and non-small cell lung carcinoma.